U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07525401) titled 'Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral Hepatitis' on March 31.
Brief Summary: Hepatitis is an inflammatory condition of the liver that has emerged as a significant global health concern due to its widespread prevalence.
Data on ursodeoxycholic acid in acute viral hepatitis remain limited. Some studies suggest its positive effect in cholestatic phase of viral hepatitis. UDCA may reduce cholestatic symptoms like jaundice and pruritus potentially shortening hospital stay and improving patient outcomes. However, robust clinical data supporting its routine use in...